Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer

BACKGROUND: Inhibitors of the kinase mTOR, such as rapamycin and everolimus, have been used as cancer therapeutics with limited success since some tumours are resistant. Efforts to establish predictive markers to allow selection of patients with tumours likely to respond have centred on determining...

Descripción completa

Detalles Bibliográficos
Autores principales: Satheesha, Sampoorna, Cookson, Victoria J, Coleman, Louise J, Ingram, Nicola, Madhok, Brijesh, Hanby, Andrew M, Suleman, Charlotte AB, Sabine, Vicky S, Macaskill, E Jane, Bartlett, John MS, Dixon, J Michael, McElwaine, Jim N, Hughes, Thomas A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055230/
https://www.ncbi.nlm.nih.gov/pubmed/21320304
http://dx.doi.org/10.1186/1476-4598-10-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055230/
https://www.ncbi.nlm.nih.gov/pubmed/21320304
http://dx.doi.org/10.1186/1476-4598-10-19

Ejemplares similares